General Info

MediciNova is a publicly traded biopharmaceutical company focused on acquiring and developing novel small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the United States market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which it believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. The company s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancer, generalized anxiety disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Its current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline, MN-221 for the treatment of status asthmaticus and MN-166 for the treatment of multiple sclerosis. MediciNova maintains a location in San Diego, Calif.